SCHEDULE 13G/A: ARCH Venture Funds Maintain Significant Stake in Beam Therapeutics
Beneficial Ownership Disclosure
ARCH Venture Fund entities and their managing directors have disclosed a continued beneficial ownership of approximately 5.5% of Beam Therapeutics Inc.'s common stock as of December 31, 2024.
Summary
- ARCH Venture Fund IX, L.P. and ARCH Venture Fund IX Overage, L.P. collectively hold 4,540,132 shares of Beam Therapeutics Inc. common stock.
- This represents approximately 5.5% of the total outstanding common stock of Beam Therapeutics Inc.
- The beneficial ownership is shared among various ARCH entities, including ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., and ARCH Venture Partners IX, LLC.
- Managing Directors Keith Crandell, Clinton Bybee, and Robert Nelsen also report shared beneficial ownership of these 4,540,132 shares, in addition to their individual holdings.
- As of December 31, 2024, Keith Crandell beneficially owns an aggregate of 4,557,862 shares (5.5% of class), Clinton Bybee beneficially owns 4,550,630 shares (5.5% of class), and Robert Nelsen beneficially owns 4,600,747 shares (5.6% of class).
- The percentage of class is calculated based on 82,805,627 shares of common stock outstanding as of October 29, 2024, as reported in Beam Therapeutics' Form 10-Q filed on November 5, 2024.
Sentiment
Score: 5
Explanation: The document is a routine Schedule 13G filing disclosing beneficial ownership, which is a factual report and does not inherently convey positive or negative sentiment regarding the company's performance or future prospects.
Future Outlook
NA
Industry Context
This filing indicates that a prominent venture capital firm, ARCH Venture Partners, maintains a significant passive investment in Beam Therapeutics, a biotechnology company. Such disclosures are standard for large institutional investors holding over 5% of a company's stock, providing transparency on major shareholder positions within the biotech industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's continued stake, which can offer some stability or confidence, but does not indicate new strategic moves.
Key Dates
| Date | Description |
|---|---|
| 2020-02-05 | Date Power of Attorney for Mark McDonnell was filed as Exhibit 24 to a Form 3 relating to beneficial ownership of Beam Therapeutics, Inc. shares. |
| 2024-10-29 | Date as of which 82,805,627 shares of common stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2024-11-05 | Date Beam Therapeutics Inc. filed its Form 10-Q with the Securities and Exchange Commission. |
| 2024-12-31 | Date of Event Which Requires Filing of this Statement (snapshot date for beneficial ownership). |
| 2025-02-14 | Date of signing for the Schedule 13G filing and the Joint Filing Agreement. |
Keywords
Beam Therapeutics, ARCH Venture Fund, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology Investment, Venture Capital
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.